Group 1 - The pharmaceutical sector has shown strong performance recently, with healthcare and pharmaceutical stocks gaining traction on the first trading day of June [1] - The Kexin Pharmaceutical Index ETF (588700) rose over 2% as of the report, with a turnover rate exceeding 6% and a premium trading rate of 0.12% [1] - Notable stocks within the ETF include Microchip Biotech, which increased by over 14%, and several others like Shenzhou Cell, Sangfor Biopharma, and Huaxi Biotech, which saw gains of over 8% [1] Group 2 - The Kexin Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange's Kexin Biopharmaceutical Index, which includes 50 large-cap companies in the biopharmaceutical and related sectors [1] - In May, the pharmaceutical sector performed strongly, with the Shenwan Pharmaceutical Biotech Index rising by 6.42%, second only to the environmental sector [1] - The approval of 11 new innovative drugs in the last week of May indicates a peak period for innovation drugs, suggesting a positive outlook for the sector [2] Group 3 - Guojin Securities highlighted that the recent approval of 11 new innovative drugs by the National Medical Products Administration could boost the performance of related companies [2] - The ongoing support for innovative drugs from policy measures, along with significant overseas licensing deals, is expected to sustain the sector's growth [2] - Huafu Securities recommends focusing on innovative drugs as a long-term investment strategy, particularly those with clear catalysts and strong performance trends [2]

Group 1 - The core viewpoint highlights the positive market reaction to the collaboration between Bristol-Myers Squibb and BioNTech regarding the new cancer drug BNT327, with milestone payments potentially reaching $11.1 billion, which has boosted the performance of innovative drug concept stocks [1] - The performance of the Kexin Biopharmaceutical ETF (588250.SH) increased by 1.23%, with its associated index Kexin Biopharmaceutical (000683.SH) rising by 0.96%, indicating a favorable market sentiment towards the biopharmaceutical sector [1] - Notable increases in major component stocks include Microchip Biotech rising by 9.44%, Huaxi Biotech by 7.63%, and Rongchang Biotech by 4.92%, reflecting strong investor interest in innovative drug companies [1] Group 2 - Guosen Securities reported significant advancements in domestic innovative drugs, particularly focusing on bispecific antibodies and ADC technologies, with promising clinical data from Innovent Biologics and Mingji Biotech in pancreatic cancer treatments [2] - Shenwan Hongyuan highlighted Huaxi Biotech as a key player in the recombinant collagen market, benefiting from the domestic beauty trend and strong brand recognition, suggesting potential for consumer recovery [2] - Both research institutions' insights align with the performance of innovative drug and medical beauty leading companies within the Kexin Biopharmaceutical ETF [2]

Group 1 - The U.S. has announced an increase in tariffs on imported steel and aluminum from 25% to 50%, causing a strong global reaction and leading to a drop in steel stocks in Asia [2] - South Korea's trade ministry held an emergency meeting with industry leaders to discuss the potential impact of these tariffs on steel exports, which accounted for 13.1% of South Korea's total steel exports in 2024 [2] - Major steel trading partners of the U.S., including Canada and the EU, condemned the tariff increase and warned of possible retaliatory measures [2] Group 2 - In June, brokerage firms have released their "golden stocks," with over a hundred stocks recommended, particularly in the machinery and pharmaceutical sectors [3] - The machinery sector is optimistic about investment opportunities arising from the development of controlled nuclear fusion, while the pharmaceutical sector suggests focusing on CXO, specialty raw materials, and pharmacies [3] Group 3 - The second round of negotiations between Russia and Ukraine concluded with an agreement to exchange the remains of fallen soldiers and a new round of prisoner swaps [4] - Russia plans to unilaterally transfer 6,000 fallen soldiers' remains to Ukraine next week, and both sides will establish a medical committee for regular exchanges of severely injured soldiers [4] Group 4 - A surge in interest around "stablecoins" has led to numerous broker calls focusing on this topic, with several stablecoin-related stocks showing strong performance [5] - Despite the potential applications of stablecoins, there are concerns about market speculation and a lack of in-depth research from major institutions [5] Group 5 - Insurance companies have been actively increasing their stakes in high-dividend assets, particularly bank stocks, with 15 instances of stake increases reported by seven insurance firms by the end of May [6] - The current wave of stake increases is driven by the need for stable cash returns in a low-interest-rate environment [6] Group 6 - An announcement from the White House indicated that the U.S. and China are expected to hold talks regarding tariff issues [7] - The U.S. International Trade Court has blocked a tariff policy announced by Trump, stating that such powers belong exclusively to Congress [7] Group 7 - An announcement from Annier indicated that the company is planning a change in control, with the current major shareholders proposing to transfer 13.03% of their shares to a counterparty [8][17] - The stock of Annier will be suspended from trading starting June 3, with the suspension expected to last no more than two trading days [8][17] Group 8 - BYD reported a total of 382,500 new energy vehicle sales in May 2025, with overseas sales accounting for 89,000 units [28] - BAIC BluePark's subsidiary saw a 215.11% year-on-year increase in sales in May 2025, totaling 17,100 units [29] - Great Wall Motors reported May sales of 102,200 vehicles, marking an 11.78% year-on-year increase, with 32,600 of those being new energy vehicles [30]

丨 2025年6月3日 星期二 丨 NO.1 华熙生物、巨子生物舆论风波升级，美妆博主回应：不认可巨子生物的说法 每经记者｜甄素静 每经编辑｜董兴生 近日，浙江海圣医疗器械股份有限公司IPO申请获北交所受理，中信证券担任保荐机构。招股书显示， 海圣医疗专注于麻醉、监护类医疗器械的研发、生产和销售，产品广泛应用于麻醉科、ICU等临床科 室。 点评：海圣医疗冲刺北交所IPO，专注于麻醉监护器械研发等，产品应用于多临床科室，若成功上市， 或将借助资本加速技术创新与市场拓展。 NO.4 和美药业递表港交所 据港交所5月29日披露，赣州和美药业股份有限公司向港交所主板递交上市申请。和美药业于2002年成 立，截至2025年5月21日，和美药业已开发7个小分子候选药物，针对具有高度未满足需求的自身免疫和 肿瘤疾病。其中4种候选药物处于II期、III期临床试验或NDA阶段，适用于12种适应证。 6月1日晚，华熙生物在微信公众号发表长文支持"大嘴博士"（郝宇）。当日深夜，巨子生物在微信公众 号发布了一份声明，称有关"可复美"未添加重组胶原蛋白的争议，5月30日公司收到了来自"大嘴博 士"所用检测机构的道歉声明，并贴出了检验机 ...

Core Viewpoint - The ongoing public dispute between Huaxi Biological and Juzhi Biological highlights the competitive tension in the aesthetic medicine industry, particularly regarding hyaluronic acid and recombinant collagen products [3][10]. Group 1: Company Statements - Huaxi Biological issued a statement on June 1, 2023, supporting beauty blogger Dr. Hao Yu, criticizing an unnamed company for using "internet water army" tactics and threatening to disclose testing results if issues are not addressed [3][4]. - Juzhi Biological responded later that day, accepting an apology from the testing agency used by Dr. Hao Yu but asserting that they would pursue legal action against those spreading false information [3][8]. - Dr. Hao Yu contested Juzhi Biological's claims, stating that the testing agency's statement did not include an apology and questioned why Juzhi had not released its own testing results after ten days [9][10]. Group 2: Market Dynamics - The dispute is rooted in a broader competition for market share between hyaluronic acid and recombinant collagen, with Huaxi Biological's performance declining alongside the perception of hyaluronic acid as "outdated" [10]. - Huaxi Biological's revenue from functional skincare products, which include recombinant collagen, has seen significant declines of 18.45% and 31.62% in 2023 and 2024, respectively, while Juzhi Biological's "Kefumei" brand has shown strong growth with revenues of 27.88 billion and 45.4 billion in the same years [11]. - The pricing landscape for aesthetic products indicates that domestic hyaluronic acid is positioned at the lower end of the market, with prices ranging from approximately 1,000 to 2,000 yuan per unit, while recombinant collagen is priced higher, around 3,000 yuan [13][14]. Group 3: Industry Trends - The aesthetic medicine market is experiencing a shift with the introduction of new injectable materials, which has led to a decrease in hyaluronic acid's market share from 42% in 2021 to an estimated 36% in 2024 [16]. - The emergence of new materials, such as hydroxyapatite and PDRN solutions, is expected to further challenge the dominance of hyaluronic acid, although its unique properties may still provide competitive advantages [16][17].

Core Insights - The Chinese oral beauty market is expected to exceed 25 billion yuan by 2025, driven by health consumption trends and a shift from external to internal beauty solutions [1][10][20] - The market is characterized by intense competition between international brands and local companies, with a focus on innovation and traditional Chinese medicine [2][10] Market Landscape - China has become the second-largest oral beauty consumption market in East Asia, accounting for nearly one-third of the Asia-Pacific region [2][10] - Despite a slowdown in growth, the projected market size of 25 billion yuan indicates significant potential [2][10] - The industry is experiencing a "dual-drive" model, with international brands localizing their strategies and domestic companies leveraging traditional medicine [2][10] Consumer Insights - The primary consumer group is women aged 31-40, but younger consumers aged 18-23 show a higher interest in oral beauty products [3][10] - The rise of "punk health" among Gen Z consumers emphasizes the desire for scientifically validated ingredients and enjoyable consumption experiences [3][10] - Emerging markets in second- and third-tier cities are driving changes in product strategies, with a notable increase in repurchase rates for "food-medicine homology" products [3][10] Product Evolution - The industry is transitioning from marketing-driven to science-driven approaches, with three main product categories emerging: "blue hat" health foods, functional foods, and traditional supplements [4][10] - Innovative product forms like gummy candies and jelly bars have seen a 217% year-on-year growth, appealing to younger consumers' preferences [4][10] - A focus on effective ingredients and enjoyable consumption experiences is reshaping product offerings [4][10] Ingredient Competition - Plant extracts and collagen account for 60% of the market share, with local brands innovating using traditional Chinese medicine [5][10] - Probiotics have emerged as a significant trend, with a sales growth rate of 89%, aligning with consumer interests in holistic health [5][10] - B vitamins have captured a 32% market share in the anti-hair loss segment, showcasing the effectiveness of combined formulations [5][10] Future Outlook - Regulatory policies are becoming stricter, pushing companies to enhance their formulations and marketing strategies [6][10] - Future competition will focus on penetrating second- and third-tier cities, developing products for specific consumer needs, and innovating product forms [6][10] - The intersection of traditional health wisdom and modern biotechnology is expected to drive the evolution of the oral beauty market in China [6][10]

Core Viewpoint - The dispute over the ingredients in medical beauty products is escalating, particularly between Huaxi Biological and Juzhi Biological, with accusations of misleading information and legal threats being exchanged [1][5][6]. Group 1: Company Statements - Huaxi Biological issued a statement supporting Dr. Hao Yu, indicating that they had confirmed the authenticity of the testing reports and would cooperate with regulatory bodies if needed [2][3]. - Huaxi Biological accused Juzhi Biological of using online marketing tactics to undermine competition and suggested that they are prepared for a "real business war" [1][4]. - Juzhi Biological responded by stating that they would pursue legal action against those spreading false information and emphasized their commitment to consumer interests [1][5]. Group 2: Product Controversy - Dr. Hao Yu claimed that the product "Kefumei" from Juzhi Biological contained only 0.0177% of recombinant collagen, which does not meet regulatory standards for labeling as a non-trace component [3]. - Huaxi Biological highlighted that their products have the highest number of medical device certifications in the industry, asserting that there is no evidence to support the safety of recombinant collagen over hyaluronic acid [4]. Group 3: Financial Performance - Juzhi Biological reported significant revenue growth from 2022 to 2024, with revenues of 2.364 billion, 3.524 billion, and 5.539 billion yuan, and net profits of 1.002 billion, 1.452 billion, and 2.062 billion yuan respectively [6]. - In contrast, Huaxi Biological experienced a decline in both revenue and net profit for 2024, with revenues of approximately 5.371 billion yuan (down 11.61%) and net profits of about 174 million yuan (down 70.59%), marking their worst performance since going public [7]. Group 4: Market Reaction - Following the controversy, Juzhi Biological's stock price fell by 18.07% from its peak on May 20, closing at 68.25 HKD per share on June 2, reflecting market concerns over the ongoing disputes [6].

Core Viewpoint - The ongoing dispute between Hyaluronic Acid and recombinant collagen has gained significant attention, particularly involving major players in the medical aesthetics industry, Huaxi Biological and Juzhi Biological, leading to market volatility and investor caution [1][8]. Company Responses - Huaxi Biological expressed support for Dr. Hao Yu, emphasizing the importance of consumer rights and the integrity of product testing, while also indicating that they have conducted thorough evaluations of the claims made by Dr. Hao [2][5]. - Juzhi Biological issued a statement condemning Huaxi Biological's accusations as malicious and unfounded, highlighting their commitment to consumer trust and the integrity of their products [2][3]. Market Reaction - Following the controversy, Juzhi Biological's stock price fell over 5.6% on June 2, closing at 68.25 HKD per share, with a market capitalization of 731 billion HKD, reflecting investor concerns about the ongoing dispute [1][8]. Testing and Standards - The testing report that Dr. Hao Yu referenced was clarified by the testing agency, stating it was not legally valid for public proof and lacked comprehensive methodology, which raised questions about the reliability of the results [3][7]. - The lack of unified testing standards in the recombinant collagen industry has been highlighted as a significant issue, contributing to consumer distrust and regulatory challenges [7][9]. Industry Implications - The incident has exposed vulnerabilities in the regulatory framework and testing standards for the recombinant collagen sector, prompting discussions about the need for clearer guidelines and industry standards [7][9]. - The National Medical Products Administration has initiated the development of industry standards for recombinant collagen testing, indicating a move towards greater regulatory oversight [7].

Core Viewpoint - The controversy surrounding the collagen content in the product "Collagen Stick" from the brand Kefu Mei, owned by Giant Biological (02367.HK), has intensified due to allegations of misleading advertising and low actual collagen levels compared to what is claimed [1][4]. Group 1: Controversy and Responses - Beauty blogger "Big Mouth Doctor" (Hao Yu) claims that the actual collagen content in Kefu Mei's product is only 0.0177%, significantly lower than the advertised "≥0.1%" [4][5]. - Giant Biological issued a statement acknowledging an apology from the testing agency used by "Big Mouth Doctor" and stated that they are pursuing legal action against those spreading false information [3][6]. - The company has sent products to multiple testing agencies for verification, but results are still pending due to the complexity of the testing process [3][6]. Group 2: Financial Performance and Market Impact - Giant Biological has shown steady revenue growth from 2020 to 2024, with revenues increasing from 1.19 billion to 5.54 billion yuan, and net profits rising from 826 million to 2.06 billion yuan [6]. - The Kefu Mei brand accounted for 82% of Giant Biological's total revenue in 2024, with its revenue reaching 4.54 billion yuan [6]. - The ongoing controversy coincides with the 618 e-commerce promotion period, raising concerns among industry experts about potential impacts on Giant Biological's performance [6]. Group 3: Industry Context and Competitor Actions - Competitors like Huaxi Biological (688363.SH) and Jinbo Biological (832982.BJ) have higher R&D expenditure ratios at 8.68% and 4.94%, respectively, compared to Giant Biological's 1.9% [7]. - Huaxi Biological publicly supported "Big Mouth Doctor" and has conducted its own testing on the allegations, emphasizing the importance of product integrity and transparency [10][11]. - Huaxi Biological has criticized the overhyped claims surrounding recombinant collagen, suggesting that such narratives lack scientific backing and may mislead consumers [11].

Core Viewpoint - The conflict between Huaxi Biological (688363.SH) and Juzhi Biological (02367.HK) is escalating from subtle accusations to open confrontation, with both companies making public statements regarding the controversy surrounding the "Kefumei" product and its alleged lack of added recombinant collagen [2][3][8]. Group 1: Huaxi Biological's Position - Huaxi Biological publicly supports Dr. Hao Yu, stating that his company, Shanghai Liuyue Medical Technology Service Co., is an important member of the Huaxi ecosystem, and they will provide legal protection [2][4]. - The company claims to have conducted thorough evaluations and multiple tests on the materials provided by Dr. Hao, and has obtained results from third-party institutions [4][7]. - Huaxi Biological accuses Juzhi Biological of engaging in malicious competition and using online tactics to undermine its reputation, asserting that they are prepared for a transparent business battle [7][8]. Group 2: Juzhi Biological's Response - Juzhi Biological asserts that it received an apology from the testing agency used by Dr. Hao, which clarified that it never authorized the use of the test report and demanded that Dr. Hao cease using it to avoid public misinformation [2][8]. - The company emphasizes that the testing report's results are influenced by various factors and should only be considered as reference values, indicating that the methodology used was flawed [8][12]. - Juzhi Biological expresses shock and disappointment at Huaxi Biological's accusations, labeling them as malicious and harmful to consumer trust in domestic brands [13][14].